Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01032850 · ClinicalTrials.gov registry record · Phase 2
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01032850 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 15 participants.
The verdict
NCT01032850, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: * how effective this combination of study drugs will be in treating HCC * how long subjects respond to these study drugs * what types of side effects can be expected, and * how severe the side effects are All subjects in this study will receive: * Sorafenib twice a day by mouth * Capecitabine twice a day by mouth Treatment will be given in a 28-day treatment cycle. Subjects will take sorafenib every day of the cycle. Subjects will take capecitabine on days 1-7 and 15-21 of the cycle
Interventions
- DRUG Sorafenib & Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-09 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01032850
The ClinicalTrials.gov registry entry for NCT01032850 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib & Capecitabine is the first listed.
NCT01032850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01032850 about?
NCT01032850 is a clinical study titled "Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma". This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: * how effective this combination of study drugs will be in treating HCC * how long subjects respond to these study drugs * what types of side effects can be expected, and * how severe the side ef...
What is the current status of trial NCT01032850?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-09. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01032850?
The interventions under investigation include: Sorafenib & Capecitabine (DRUG).
Who is sponsoring clinical trial NCT01032850?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.